{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-039201","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2021-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.501508+00:00","generated_at":"2026-06-30T01:07:35.895065+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cyclerion Q2 net loss $16.2M; cash $70M; pipeline advances; praliciguat licensed to Akebia for up to $585M milestones","bullets":["Net loss of $16.2M in Q2 2021 vs $19.5M in Q2 2020; cash $70M as of June 30, 2021, up from $45M in March.","CY6463 Phase 2a trial initiated in Alzheimer's with vascular pathology (ADv); Ph1b in CIAS start-up; MELAS data expected by year-end 2021.","Exclusive global license of praliciguat to Akebia Therapeutics; Cyclerion eligible for up to $585M milestones plus tiered royalties.","Closed $18M private placement with EcoR1, Slate Path, MFN, Invus, and others; net $12.5M from ATM offering in Q2.","Errol De Souza appointed to Board of Directors; expanded Beacon Biosignals partnership for biomarker identification."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-039201","json":"https://secwatch.observer/filing/0001564590-21-039201.json","markdown":"https://secwatch.observer/filing/0001564590-21-039201.md","text":"https://secwatch.observer/filing/0001564590-21-039201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000156459021039201/0001564590-21-039201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000156459021039201/cycn-8k_20210729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T01:07:35.895065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}